Deals
The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it will attend several upcoming international conferences.
Heidelberg Pharma AG reported on the first nine months of fiscal year 2019 and the Group’s financial figures.
Datavant, the leader in helping healthcare organizations connect and share health data, announced a series of corporate updates.
UCB indicates the deal is part of its strategic growth plan, dubbed the “Accelerate and Expand” phase since 2019.
Global Blood Therapeutics, Inc., announced that on October 1, 2019, the compensation committee of GBT’s board of directors granted 12 new employees options to purchase an aggregate of 24,600 shares of the company’s common stock with a per share exercise price of $46.99 and restricted stock units for an aggregate of 57,050 shares of the company’s common stock.
Innovate Biopharmaceuticals, Inc. and RDD Pharma, Ltd announced that the two companies entered into a definitive merger agreement pursuant to which Innovate agreed to acquire all of the outstanding capital stock of privately-held RDD in exchange for a combination of common and preferred shares.
Oxford start-up developing novel therapeutics based on deep expertise in immune cell regulation
Sareum Holdings plc, the specialised small molecule drug development business, will announce its results for the full year ended 30 June 2019 on Tuesday 15 October.
Sensyne Health plc, the British clinical AI technology company, announces that its Annual Report and Accounts for the year ended 30 April 2019 is now available on the Group’s website at www.sensynehealth.com/investors.
Sensyne Health plc, the British Clinical AI technology company, announces its audited full year results for the 12 months ended 30 April 2019.